Incyte has announced the discontinuation of its MRGPRX4 (INCB000547) program for cholestatic pruritus (CP) and a pause in the Phase 2 trial of MRGPRX2 (INCB000262) for chronic spontaneous urticaria (CSU). The decision, revealed on Tuesday afternoon, led to a significant decline in Incyte's stock value.
The biopharmaceutical firm stated that data from the Phase 2 study of MRGPRX4 in treating cholestatic pruritus, a liver disorder characterized by intense itching, did not warrant further development. Incyte has shared the data with the Food and Drug Administration (FDA) and is working with the agency to determine the subsequent course of action.
Pause in Urticaria Trial
Simultaneously, Incyte has paused enrollment in the ongoing Phase 2 trial of MRGPRX2 for chronic spontaneous urticaria, commonly known as chronic hives. This decision was prompted by "the observation of certain in vivo preclinical toxicology findings." In vivo toxicology assesses the toxic effects of a drug on a living organism, typically an animal, before human trials proceed.
Impact and Next Steps
The company's stock experienced a downturn following the announcement. Incyte is collaborating with the FDA to evaluate the data from both programs and determine future steps. These changes reflect the inherent risks and challenges in pharmaceutical research and development.
